CD8A and cancer: In contrast to CD4+ T cells, if CD8+ T cells were above 13, 5-year OS probability was around 90% and RFS rate was above 95% in cancer patients, whereas only 45% of OS and 50% of RFS in CD8+ T cells ≤13 cancer patients (Figure 5B).